Your pain tolerance is declining, and your genes may be the reason nobody told you.

Your COMT gene encodes an enzyme that breaks down catecholamine stress hormones (epinephrine and norepinephrine) in your brain and nervous system. When COMT is working efficiently, stress hormones spike briefly during a challenge and then clear out, returning you to baseline. This constant cycling is normal and healthy.

The Val158Met variant, carried by roughly 25% of people with European ancestry, slows COMT enzyme activity significantly. When you have the slow-metabolism version (homozygous Met), your stress hormones accumulate rather than clear. Chronically elevated epinephrine and norepinephrine amplify pain signal transmission in your trigeminal and dorsal horn neurons, lowering your pain threshold and increasing central sensitization. Over time, the same physical stimulus that used to feel like a 4/10 now feels like a 7/10.

You experience this as a gradual tightening of your nervous system. Sounds feel louder. Lights feel brighter. Small aches feel sharper. Your muscles stay tense because stress hormones never fully clear. When combined with aging, inflammation, or poor sleep, this slow clearance creates a perfect storm for declining pain tolerance.

Your OPRM1 gene encodes the mu-opioid receptor, which sits on pain-processing neurons throughout your nervous system. When you experience pain, your brain releases endogenous opioids (endorphins, enkephalins) that bind to these receptors and dampen the pain signal. A healthy OPRM1 means your receptors are highly responsive; pain relief is efficient and natural.

The A118G variant (G allele), present in roughly 10-15% of people with European ancestry, produces a receptor that is less sensitive to your body’s own opioids. Your brain and body are still producing endogenous pain relief molecules, but your opioid receptors don’t respond as strongly to them. This effectively lowers your pain threshold without any obvious cause on bloodwork; your opioid levels may be normal, but your receptors aren’t receiving the signal efficiently.

You experience this as a baseline inability to ‘override’ minor pain the way you used to. Exercise soreness lingers longer. Migraines feel more intense. Even dull aches don’t fade into the background. Over time, you notice you’re reaching for over-the-counter pain relievers more frequently, or that doses that used to work no longer do.

Your MTHFR gene encodes an enzyme that catalyzes a critical step in the methylation cycle, producing methylfolate that your nervous system needs to synthesize neurotransmitters and regulate inflammation. MTHFR also indirectly controls nitric oxide production, which keeps blood vessels relaxed and reduces neuronal excitability. When MTHFR is working efficiently, pain pathways remain calm and well-regulated.

The C677T variant, carried by roughly 40% of people with European ancestry, reduces MTHFR enzyme efficiency by 35-40%. This impairment raises homocysteine (a pain-pathway neurotoxin), reduces methylation of pain-regulating genes, and lowers nitric oxide production. The result is increased neuronal excitability in your pain-processing regions and chronic low-grade inflammation in the nervous system. Your pain threshold doesn’t drop acutely; it creeps downward over months or years as neuronal inflammation accumulates.

You experience this as a slow worsening of baseline pain sensitivity combined with a new difficulty recovering from physical activity. Your nervous system feels ‘inflamed’ or ‘raw.’ Pain radiates more easily. You may also notice brain fog, fatigue, or mood shifts, all of which co-occur because the same methylation impairment affects multiple neurotransmitter systems.

Your BDNF gene encodes brain-derived neurotrophic factor, a protein that supports the survival of existing neurons and encourages growth of new neurons. In pain pathways, BDNF plays a complex role: high levels support neuroplasticity and learning, but excessive BDNF in pain-processing regions drives central sensitization, where your nervous system ‘learns’ to amplify pain signals. The balance is critical.

The Val66Met variant, carried by roughly 30% of the population, alters BDNF activity-dependent secretion. Met-allele carriers have reduced BDNF-mediated stress recovery and heightened susceptibility to central sensitization, meaning their nervous system is more likely to ‘lock in’ pain amplification once triggered. If you experience a major stressor, injury, or illness, a Val66Met variant makes it harder for your nervous system to reset back to baseline pain sensitivity. Your tolerance drops and stays down.

You experience this as a plateau in pain tolerance. An acute injury or illness temporarily worsens pain, as expected. But weeks later, when the injury has healed and the illness has passed, your pain sensitivity doesn’t return to where it was. Your new baseline is lower. Over time, with multiple small injuries or stressors, each one leaves your nervous system slightly more sensitized than before.

Your TRPV1 gene encodes a sensory receptor that sits on the endings of pain-sensing nerves (nociceptors) throughout your body. This receptor detects heat, pressure, and chemical irritants, and when activated, it fires a pain signal toward your spinal cord and brain. A normal TRPV1 threshold means your nociceptors only fire in response to genuine tissue-threatening stimuli. A lower threshold means they fire more easily, in response to smaller temperature changes or lighter pressure.

Gain-of-function TRPV1 variants, present in roughly 25-30% of the population, lower the activation threshold of nociceptors. Your pain-sensing nerves become more excitable, firing pain signals in response to stimuli that should register as mild discomfort. You don’t have more pain nerves; the ones you have are simply more trigger-happy. This is especially pronounced in response to heat, pressure, and chemical irritants like spicy food or strong fragrances.

You experience this as an unexplained increase in sensitivity to temperature (hot showers feel too hot, cold feels sharper). You also notice that pressure that used to feel like a massage now feels like it borders on painful. Tight clothing bothers you more. Over time, you begin avoiding activities or temperatures that you used to tolerate, and this avoidance can drive further nervous system sensitization.

Your GCH1 gene encodes GTP cyclohydrolase 1, an enzyme that synthesizes tetrahydrobiopterin (BH4), a critical cofactor for multiple pain-modulating neurotransmitter synthesis pathways. BH4 is required for nitric oxide synthase (which relaxes blood vessels and calms neurons), for tyrosine hydroxylase (which produces dopamine, a pain-inhibitor), and for tryptophan hydroxylase (which produces serotonin, another key pain-dampener). Without adequate BH4, all three of these pathways stumble. Your pain modulation capacity drops.

GCH1 variants, present in roughly 15-20% of the population, reduce BH4 production capacity. When you face physical or emotional stress, your demand for BH4 spikes, but your body cannot ramp up production quickly enough, leaving you depleted in dopamine and serotonin exactly when you need them most. The result is that pain signals go unanswered; there simply aren’t enough pain-inhibiting neurotransmitters available to suppress them. Your pain tolerance drops under stress in particular.

You experience this as a clear correlation between stress and pain sensitivity. When you’re well-rested and calm, pain is manageable. After a stressful day or a poor night’s sleep, the same physical sensation feels much sharper. Over time, if stress becomes chronic, your baseline pain tolerance gradually drops because you’re constantly in a state of BH4 depletion.